Literature DB >> 3008894

Myeloperoxidase-deficient polymorphonuclear leucocytes. Longitudinal study during the preremission--and the remission phase in acute myeloid leukaemia. Comparison to neutrophil alkaline phosphatase (NAP) activity.

K Bendix-Hansen.   

Abstract

Serial determinations of MPO and NAP activities in granulocytes were performed during the preremission phase and the remission phase in patients with AML. Of 18 patients examined during the preremission period, 9 showed an increased number of MPO deficient PMN. Complete remission was attained in 4 of these, in 3 the number of abnormal granulocytes changed to normal 7, 7 and 14 days before and in 1 simultaneously with the attainment of complete remission. In the other patients no changes in granulocyte MPO activity occurred during the preremission period. All 20 patients examined during complete remission showed a normal MPO activity in granulocytes. Of eight patients, who at diagnosis had shown abnormal granulocyte MPO activity, three developed relapse. In two of these, an increased number of MPO deficient PMN reappeared two and eight months prior to and in one simultaneous with clinical and laboratory suspicion of relapse. A statistically significant relation between low NAP scores and an increased number of MPO deficient PMN was found (P = 0.011). Serial determinations of MPO activities in PMN, although restricted to cases of AML with initially abnormal values, may prove helpful in predicting achievement of complete remission and may furthermore prove to be useful as an indicator of early relapse.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3008894     DOI: 10.1007/bf00321083

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  9 in total

1.  A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and marrow.

Authors:  L S KAPLOW
Journal:  Blood       Date:  1955-10       Impact factor: 22.113

2.  Isolation of lymphocytes, granulocytes and macrophages.

Authors:  A Bøyum
Journal:  Scand J Immunol       Date:  1976-06       Impact factor: 3.487

3.  The relative merit of various cytochemical quantities and manual differential count in predicting remission following chemotherapy of patients with de novo acute myeloblastic leukemia.

Authors:  S Avnstrøm; E Ralfkiar; P Winkel; N I Nissen
Journal:  Am J Clin Pathol       Date:  1985-01       Impact factor: 2.493

4.  Myeloperoxidase-deficient neutrophils in acute myeloid leukaemia.

Authors:  D Catovsky; D A Galton; J Robinson
Journal:  Scand J Haematol       Date:  1972

5.  Letter: Substitute for benzidine in myeloperoxidase stains.

Authors:  I S Kaplow
Journal:  Am J Clin Pathol       Date:  1975-03       Impact factor: 2.493

6.  Studies on abnormal polymorphonuclear neutrophils in acute myelogenous leukemia: clinical significance and changes after chemotherapy.

Authors:  T Suda; T Onai; T Maekawa
Journal:  Am J Hematol       Date:  1983-08       Impact factor: 10.047

7.  Automated cytochemistry in the prediction of remission following chemotherapy of patients with de novo acute myeloblastic leukemia.

Authors:  P Winkel; T Olesen; N I Nissen
Journal:  Am J Clin Pathol       Date:  1982-01       Impact factor: 2.493

8.  Myeloperoxidase-deficient polymorphonuclear leucocytes. (I) Incidence in untreated myeloid leukaemia, lymphoid leukaemia and normal humans.

Authors:  K Bendix-Hansen; H Kaspersen Nielsen
Journal:  Scand J Haematol       Date:  1983-05

9.  Myeloperoxidase-deficient polymorphonuclear leucocytes. (II) Longitudinal study in acute myeloid leukaemia, untreated, in remission and in relapse.

Authors:  K Bendix-Hansen; H K Nielsen
Journal:  Scand J Haematol       Date:  1983-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.